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CHAPTER 1: 
Introduction 
2 
Overview 
 
Diabetes mellitus affects a huge proportion of people; about 6% of the population 
in the US had diabetes in 2007 (16). Diabetes promotes dyslipidemia, an imbalance in the 
circulating levels of lipids and lipoproteins, and diabetes is one of the leading risk factors 
for coronary artery and peripheral vascular diseases (11, 51, 52).  There are two types of 
diabetes; type 1 diabetes accounts for about 10% of diagnosed cases and type 2 accounts 
for about 90% (11).  Diabetic patients react differently to stents and there is a great need 
to enhance the treatment.  The goal of this project was, and continues to be, to create a 
“diabetic” environment in which stents can be tested to characterize the potential of the 
stent to continue with animal testing.  
 
Cardiovascular Disease 
Early in the progression of cardiovascular disease, endothelial dysfunction occurs.  
The progression of endothelial dysfunction begins when the endothelial cells are 
activated and express adhesion molecules such as intracellular adhesion molecule 
(ICAM).  From here the leukocytes stick to the adhesion molecules and migrate into the 
vessel.  The smooth muscle cells (SMCs) then migrate towards the intima and proliferate 
and the beginning of a lesion is formed (32).  Once the circulating lipoproteins bind, there 
is a sustained inflammatory response and the lesion starts to grow and calcify; lipids 
begin to accumulate and soon a significant lesion is formed.  This build-up of plaque is 
known as atherosclerosis and is illustrated in Figure 1.1.  When this first occurs the vessel 
will try to compensate by remodeling and expanding so the lumen remains the same size.  
However, eventually the blood vessel narrows and blood flow is affected.  There are two 
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main problems due to this progression.  First, the narrowing of the vessel impedes the 
blood flow and the tissue doesn’t receive the proper amount of oxygen and nutrients.  
Second, the lesion can rupture and create a clot.   
 
                   Figure 1.1- Progression of atherosclerosis in cardiovascular disease (1).   
The current treatments for cardiovascular disease are lifestyle modifications, 
drugs, angioplasty and/or stents, and bypass surgery.  In angioplasty a balloon is used to 
push the plaque against the vessel wall and often times a stent remains to prevent 
restenosis.   Stents are a huge area of research and are widely used in the clinic (cite). 
Many new materials, such as biodegradable and drug eluting stents are currently being 
researched (48).  Biodegradable stents will provide the support long enough to prevent 
restenosis, but degrade in time to allow for endothelialization- preventing late stent 
thrombosis. Drug eluting stents are used to prevent the proliferation of cells, or 
restenosis, but often times they prevent endothelialization and healing.  Once a desired 
stent has been developed, it must go through the FDA prior to market approval in the 
U.S. 
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In order to obtain FDA approval to market, much testing is required.  Kristen 
Cardinal’s Tissue Engineering Laboratory at California Polytechnic State University has 
created an in vitro blood vessel mimic (BVM) to test stents and obtain data before the 
stent is tested in animals.  The BVM consists of an 8-roller pump, a reservoir for media 
and a bioreactor for the engineered vessel.  This set up can be seen in Figure 1.2.  This is 
a very valuable tool to save time, money and resources.  Stents can be tested in a more 
high throughput manner in vitro, and the stents that show the most potential can then be  
tested further in animal models.  
 
               Figure 1.2- Blood vessel mimic as used to test stent characteristics.   
 
 
Diabetes Mellitus 
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There are two different types of diabetes; type 1 diabetes and type 2 diabetes.  
Type 2 diabetes is often associated with obesity, lack of exercise, and unhealthy eating 
choices (11).  In this type of diabetes, insulin sensitivity is decreased, which ultimately 
leads to inadequate release of insulin and β-cell failure.  This can be apparent at either the 
insulin receptor level or postreceptor signaling (11, 25).  There are a few leading causes 
of type 2 diabetes.  The first is a decrease in the ability to increase the GLUT4 uptake of 
glucose.  This could be due to an increase in triglycerides (TG) in the muscle due to an 
unhealthy diet causing hyperinsulemia (11).  Initially, more glucose will be uptaken into 
the skeletal muscle and this will increase lipogenesis and repress fatty acyl CoA 
oxidation (11).  Some of these byproducts, diacylglycerol and ceramide, will stimulate 
signaling pathways as they accumulate, which disrupts signaling from the insulin receptor 
(IR) and insulin receptor substrate (IRS) proteins (11).  This will then create insulin 
resistance in the skeletal muscle (11).  The second cause of obesity-induced insulin 
resistance is the decreased ability of insulin to repress hepatic glucose production (11).  
The liver creates glucose through glycogenolysis and gluconeogenesis (11).  Insulin 
represses the enzymes in both of these pathways (11).  The increase in visceral adipose 
tissue can induce the effects of lipotoxicity by releasing cytokine tumor necrosis factor-α 
(TNF-α), which can disrupt insulin signaling pathways (11).  The third common reason 
for insulin resistance is the inability of insulin to repress hormone-sensitive lipase (HSL) 
or increase lipoprotein lipase (LPL) in adipose tissue (11).  High HSL and low LPL are 
commonly found in people with insulin resistance (11).  This dyslipidemia is 
characterized as hypertriglyceridemia with large TG-rich VDL particles that are produced 
by the liver (11). These particles are digested efficiently creating small dense LDL 
particles, known to be atherogenic (11).  HDL, which protects against vascular disease, 
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has also been shown to take on TG instead of cholesterol, which shortens the half-life of 
HDL and decreases the HDL levels (11).   
Type 1 diabetes is an autoimmune disease of the β-cells and is often onset in 
childhood. β-cells produce insulin, and in Type I diabetics beta cells are destroyed, so 
these patients are insulin dependent and need exogenous insulin to prevent ketosis.  It is 
believed that the initial stimulus can be due to a viral infection, which recruits leukocytes 
to islets or dendritic cells in lymph that drain from islets and will present antigens to T-
cells.  This leads to insulitis, or inflammation of insulin producing cells, and ultimately β-
cell destruction.  This disease can also be due to cytotoxicity, and it has been found that 
NKp46, a receptor on CD8+ T-cells, is required for β-cell toxicity in animal models.  The 
inappropriate T-cell activation can also be caused by a couple of factors.  First, glutamic 
acid decarboxylase 65 (GAD65) is an enzyme found outside of cells; often times in type 
1 diabetes the T-cells are reactive to GAD65.  Second, the major histocompatibility 
complex (MHC) genes may cause inappropriate T-cell activation.  Third, there can be an 
inappropriate expression of the insulin gene in the thymus, which is where the T-cells 
mature.  All of these can lead to type 1 diabetes.   
 
Endothelial Cell Biology and Dysfunction  
In the use of an in vitro BVM it is important to understand the structure and 
function of the artery that is being mimicked.  The blood vessel system can be subdivided 
into three different components: arterial system, venous system and microcirculation 
(11).  There are a couple of key differences between each of these blood vessel systems.  
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The arterial system distributes blood from the heart to the tissue, the venous system 
delivers blood to the heart from the tissue, and the microcirculation system connects the 
arterial and venous systems and allows for waste and nutrient exchange (11).  The 
capillaries of the microcirculation system consist of fenestrated and non-fenestrated 
endothelial cells (ECs) as well as continuous and discontinuous ECs (5). Both the venous 
and arterial systems are composed of only non-fenestrated, continuous endothelium (ECs 
are tightly connected and surrounded by a continuous basement membrane) and the 
arterial system also contains many tight junctions (5, 6).  The ECs of the venous system 
are phenotypically shorter and wider than those of the arterial system.  The pressure in 
the venous system is not as high as the arterial pressure and the venous system has valves 
to prevent the back flow of blood.  The venous system also has thinner walls.  For the 
reminder of this report, the arterial system will be the primary focus because the problem 
lies in getting blood out to the body. 
The artery is made of three layers: adventitia, media and intima, as illustrated in 
Figure 1.3.  The adventitia, the outermost layer, is composed of collagen, fibroblasts, 
nerves (in the larger arteries) and vasovorum.  The middle layer, the media, is composed 
of smooth muscle cells (SMC) and elastin.  The SMCs align perpendicular to blood flow 
and therefore, wrap around the vessel.  The inner layer, the intima, is composed of a 
basement membrane and endothelium, which is composed of ECs.  The ECs within the 
artery align parallel to flow and are supported by the basement membrane.  The ECs are 
the blood contacting surface and tell the smooth muscle cells (SMCs) when to constrict 
(4). The major function of the artery is to act as a conduit for blood, to provide an anti-
thrombogenic lining, control blood cell trafficking, control permeability and help control 
flow through dilation and constriction (4, 5).  
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                                          Figure 1.3 – The three arterial layers- adventitia, media and intima (1).   
When using ECs in the laboratory or in tissue engineering, it is important to note 
their source.  ECs from capillaries in the skin, liver and brain all have very distinctive 
properties and different surface protein expressions (15). The control of the plasticity of 
the artery- and vein-specific properties is not completely understood.  There are studies 
supporting the hypothesis that these properties are epigenetically programmed before 
blood flow.  For example, the stimulation of arterial ECs with oxidized LDL had much 
greater effects on the adhesion, proliferation and apoptosis than ECs from a human 
saphenous vein (5).  However, as in coronary artery bypass grafting, when veins are 
grafted into the arterial system their walls thicken, permeability decreases, endothelial 
nitric oxide synthase (eNOS) increases and thrombomodulin decreases (6).  This lends 
support to the hypothesis that structure and function are controlled by the 
microenvironment.  It is likely that the EC phenotype is controlled by both the 
microenvironment and epigenetics.  Input from the microenvironment can be attributed to 
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shear stress, growth factors, cytokines, chemokines, hormones, nitric oxide, oxygen and 
reactive oxygen species (5).  The phenotype of ECs can be determined or measured 
through cell shape, protein expression, migration, proliferation, apoptosis, vasomotor 
tone, hemostatic balance, release of inflammatory mediators, and leukocyte adhesion (5).   
Endothelial cells are very important in the regulation of blood flow.  This is 
controlled by initiating/modulating an inflammatory response, activating leukocyte 
trafficking, vasomotion and coagulation (33, 36).  ECs express receptors for mediators on 
their surface and they can release biologically active mediators such as cytokines and 
hematopoietic growth factors (36).  They produce and release nitric oxide (NO) and 
prostacyclin (PGI2) both known vasodilators; as well as vasoconstrictors such as 
endothelin, platelet –activating factor (PAF), and angiotensin II (13, 15, 25).  These 
compounds are regulated at the gene level; they are not present in the cell until a receptor 
causes gene transcription (15). The endothelium in arteries is not highly permeable due to 
the tight junctions (5).  The endothelium can induce permeability when inflamed by the 
formation of intracellular gaps.  The formation of gaps can be enhanced by histamine, 
serotonin, bradykinin and VEGF (5).   
Leukocyte trafficking is accomplished through a multi-step process including 
attachment, rolling arrest and transmigration (5).  After the initial attachment, the 
leukocyte interacts with endothelial E- and P-selectin to mediate the rolling (5). Next the 
leukocyte integrins interact with ICAM-1 and vascular cell adhesion molecule (VCAM)-
1 (5).  Finally, transmigration is mediated through the use of CD99, PECAM-1 (CD31) 
and junctional adhesion molecule-1 (5).   E- and P-selectin are not expressed in quiescent 
ECs (5).  ICAM-1 and VCAM-1 are expressed in areas that are predisposed to 
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atherosclerosis, however they can be induced by activation agonists such as 
lipopolysaccharide or tumor necrosis factor (TNF)-α (5).  A study on mice showed that 
TNF-α can upregulate ICAM-1, VCAM-1, E-selectin and P-selectin (5).  The increase in 
cell-adhesion molecules was correlated with increased adhesion of leukocytes (5).  
Vasomotion is imperative in vessels.  Healthy ECs release NO.  NO diffuses to 
the SMCs to control vasomotion.  NO is also active in the inhibition of platelet activation, 
prevention of SMC proliferation, monocyte adhesion, platelet aggregation and EC 
apoptosis.  NO release is regulated by physical activity, shear stress and hormones.  PGI2 
is also found in the endothelium and helps to inhibit platelet aggregation and prevent 
proliferation of vascular smooth muscle cells (13).  Endothelium-derived hyperpolarizing 
factor (EDHF) is another important vasodilator; even when other factors are inhibited, 
this can persist.  Endothelin (ET)-1, produced by ECs, causes vasodilation at lower 
concentrations and vasocontraction at higher concentrations (13).  ET-1 enhances the 
effects of other vasoconstrictors such as serotonin and norepinephrine.  After 
metabolization of ET, NO is helpful to restore the normal vasotone (13).  Acetylcholine, 
histamine and serotonin activate a receptor on SMCs and platetlets to counteract the 
effects of NO and PGI2 (13).  Angiotensin II is also important for vasoconstriction.  It 
helps maintain vascular tone, tissue formation and structure.  Angiotensin-converting 
enzyme (ACE), which converts angiotensin I to angiotensin II, is involved in the 
breakdown of the stimulus bradykinin, needed for NO and PGI2 release (13).  
ECs are imperative to maintain blood in a fluid state, they protect the circulating 
blood from being exposed to prothrombotic subendothelial material (21).  ECs release 
several important mediators to prevent platelet activation, adhesion and aggregation (21).  
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For anti-coagulation purposes, ECs in arteries express thrombomodulin, endothelial 
protein C receptor (EPCR), tissue-type plasminogen activator (t-PA), ecto-ADPase, 
prostacyclin, and NO (5). Vasodilators, PGI2 and NO, help to prevent platelet adherence 
to the endothelium.  NO has also been shown to limit the adhesion of monocytes, 
preventing the build up of atherosclerotic plaque.  NO and PGI2 are enhanced by 
thrombin, bradykinin, serotonin, PDGF and IL-1 (13).  For procoagulation, ECs express 
tissue factor, plasminogen activator inhibitor (PAI)-1, von Willebrand factor (vWF), 
cellular adhesion molecules, and protease activated receptors (5). Angiotensin II up-
regulates the expression of adhesion molecules causing circulating monocytes to adhere 
to the endothelial surface.  It also leads to platelet aggregation, thrombosis and migration 
and growth of SMCs.  In healthy ECs, angiotensin II is inhibited due to the presence of 
NO, so the vessel wall is normally in a state of quiescence.   
The balance between damage and repair of the vessel is imperative for proper EC 
function (14).  The damage process is not only dependent on the migration and 
proliferation of mature ECs, but also on endothelial progenitor cells (EPCs).  There are 
three main cell types that contribute to vascular homeostasis.  Endothelial colony forming 
cells (ECFC) are highly proliferative and originate in the bone marrow (47).  ECFC can 
produce endothelial progeny, form endothelial tubes in vitro and contribute to neo-
vascularization as well as re-endothelialization (47).  The second type is circulating 
angiogenic cells (CAC).  CACs originate from the monocyte-macrophage lineage and are 
involved in the uptake of acetylated low-density lipoprotein (LDL) (47).  CACs produce 
angiogenic cytokines that contribute to vascular homeostasis (47).  The third type is 
colony-forming units (CFU) composed of myeloid progenitor cells, monocytes and T 
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lymphocytes.  CFUs are often used as a biomarker for cardiovascular disease as they 
have a high correlation with endothelial dysfunction.   
There are many factors that can lead to systemic changes of the cardiovascular 
system including hypertension, hyperglycemia and hyperlipidemia.  These cause 
disturbed flow, activation/dysfunction of ECs and ultimately inflammation, increased 
oxidative stress, reduced NO bioavailability and monocyte extravasation (6). Impaired 
NO production in conjunction with excessive oxidative stress causes a decline in NO 
bioavailability leading to EC apoptosis (47).   EC dysfunction impairs the vasomotion 
and causes procoagulation, oxidative stress and inflammation and further progression to 
atherosclerosis and diabetic complications.   
 
Endothelial Cell Dysfunction in Diabetics 
There are a couple of pathways that lead to endothelial cell dysfunction and 
complications.  The first is polyol-sorbitol; it leads to an increase in oxidant stress.  The 
second, hexosamine leads to an increase in transcription of proinflammatory cytokines.  
The third, advanced glycation end product (AGE) decreases protease degradation of 
collagen, creating a stiffer vascular wall and increasing proinflammatory cytokine 
expression and PKC activation. AGE then binds with its cellular receptor leading to the 
release of growth factors and activation of inflammatory pathways (13). AGE begins due 
to chronic hyperglycemia and decreases NO delivery to SMCs.  This can then lead to 
atherosclerosis.  AGE has been found to accumulate more quickly than normal in patients 
with diabetes (51).  The fourth pathway is direct activation of protein kinase C (PKC), 
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which leads to an increase in inflammation and oxidant stress.  PKC is activated by an 
increase in diacylglycerol levels due to hyperglycemia.  PKC then stimulates the NADPH 
oxidase enzyme leading to superoxide production and oxidative stress (13).  In an effort 
to account for all of the different pathways involved in diabetes the following hypothesis 
has been developed: there is an increase of superoxide production in ECs, which activate 
the main pathways such as PKC and AGE to lead to EC dysfunction and atherosclerosis 
(13).  This hypothesis implies that EC dysfunction in diabetic patients is complex and 
begins with an increase in oxygen free radicals and a decrease in NO bioavailability.  
This is followed by inflammation and eventually atherosclerosis. 
EC dysfunction is characterized by a decrease in vasodilation.  In diabetic 
patients, it has been found that there is a decrease in the formation of the vasodilator, 
PGI2 (13).  This occurs before any changes in the vessel structure, but can increase blood 
pressure.  NO is also decreased in active ECs.  Oxygen-derived free radicals lead to an 
increase in the degradation of NO by NADPH oxidase (13).  Diabetes also leads to the 
impairment of EDHF-dependent vasodilation (13).  ET-1 is often found to be increased in 
diabetic patients.  It has been shown that ET-1 levels correspond to the number of 
vascular complications in diabetic patients with clinical angiopathy (13).   
EC dysfunction in diabetic patients is characterized by procoagulation; platelets 
adhere to the ECs and aggregate.  Most coronary events that occur are due to less than 1/3 
narrowing of the vessel.  ECs in regions of arteries with disturbed flow are primed for 
activation by having increased levels of nuclear factor κB (NF-κB) in their cytoplasm 
that can be translocated to the nucleus to increase the expression of procoagulants (5).  
AGE’s receptor RAGE, can be activated by NF-κB leading to the expression of VCAM 
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and ICAM (51).  Diabetic patients express a number of coagulation factors that can lead 
to increased levels of fibrinogen and thrombosis (13).  There often is a defective response 
to PGI2 and NO.  With EC dysfunction, when platelets adhere to the vascular wall they 
cause vasocontraction, and proliferation and migration of SMCs.  The decrease in NO 
along with the increase in various growth factors leads to proliferation.   
EC dysfunction is also characterized by an increase in oxidative stress.  This is 
caused by the production of ROS as well as AGE/RAGE. The reaction of AGE and 
RAGE can lead to a positive feed-back loop.  AGE and RAGE induce the production of 
reactive oxygen species (ROS), which leads to NF-κB and further production of ROS and 
then more AGE products.  This leads an the increase in O2 and oxidative stress in diabetic 
vessels as well as a decrease in the bioavailability of NO (51).  
EC dysfunction is associated with inflammation as well as atherosclerosis.  EC 
dysfunction can be used as a predictor of cardiovascular events (51). Activated ECs 
increase leukocyte trafficking.  Activated ECs release cytokines, this leads to the 
accumulation of T cells and foam cells that perpetuate inflammation, lipid accumulation 
and SMC activity.  Some studies have shown that EPC numbers and function in diabetic 
patients with cardiovascular risk factors are decreased (21).  These EPCs are imperative 
for endothelial repair and function.  In summary, EC dysfunction is characterized by 
procoagulation, an increase in oxidative stress, increase in oxidative stress, increase in 
atherosclerosis and a decrease in vasodilation. 
 
Implications of Endothelial Cell Dysfunction in Diabetic Patients 
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EC dysfunction is not always associated with diabetes.  EC dysfunction is 
associated with atherosclerosis and cardiovascular disease, but one does not have to be 
diabetic to express these cardiovascular risk factors (21).  There are many conditions 
predisposing of atherosclerosis and these include dyslipidemia, hypertension and 
diabetes.  Diabetes, therefore, is a risk factor for atherosclerosis and EC dysfunction (33).  
Also, diabetic patients often have dyslipidemia and hypertension, both risk factors for 
atherosclerosis.  Therefore, a diabetic patient is at much greater risk of developing 
atheroscerosis than a healthy individual because they often times have more risk factors.  
Diabetic patients also have high glucose levels if they are not able to carefully control 
their blood sugar levels (13).  This increase in glucose level increases the superoxide 
generation and disturbs proliferation; endogenous antioxidant enzymes are then over-
expressed and there is an increase in free radicals and a decrease in NO (13).  A decrease 
in NO and increase in free radicals are both associated with EC dysfunction.  Diabetes 
and EC dysfunction are closely tied together, however, they are not mutually exclusive.  
For the purpose of this project, EC dysfunction in diabetic patients will be the main 
focus.   
There are many complications associated with diabetes and EC dysfunction.  One 
complication is retinopathies, a major cause of blindness.  There are non-proliferative as 
well as proliferative retinopathies.  In non-proliferative retinopathy microaneurisms occur 
in the capillaries and block blood supply in the retina.  As this becomes more severe, 
proliferative retinopathy develops.  Proliferative retinopathy is characterized by the 
growth of new vessels in the retina.  These vessels are very fragile and can leak blood 
causing vision blindness or vision loss.  Often times the pressure can be relieved before 
causing blindness (3).  Diabetic retinopathy is caused by a high intracellular glucose 
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concentration in retinal ECs and pericytes due to hyperglycemia causing endothelial cell 
dysfunction (11).  Diabetes can cause peripheral nerve damage due to a diminished blood 
supply to nerves.  Diabetes can also lead to reduced renal function, chronic ulcerations, 
and atherosclerosis.  
Atherosclerosis is almost always present in diabetic patients after 5-10 years (13).  
In diabetic patients, atherosclerosis tends to develop earlier than in non-diabetic patients. 
Atherosclerosis can lead to myocardial infarction and stroke.  LDL accumulates in the 
intima of the artery and activates the endothelial cells to express adhesion molecules.  
These molecules then adhere to monocytes and leukocytes, which migrate into the intima 
(24).  The monocyte derived macrophages upregulate scavenger receptors (SR) and toll-
like receptors (TLR), which initiate signaling cascades and release cytokines, proteases 
and vasoactive molecules leading to further inflammation and atherosclerotic build up.  
Pro-inflammatory cytokines, proteases and coagulation factors produced by macrophages 
as well as T cells can lead to degradation of the plaque and thrombosis.  T cells in the 
lesion lead to a Th1 response that is involved with IFN-γ and TNF, both of which have 
been shown to promote atherosclerosis.  The atherosclerotic progression can be seen in 
Figure 1.4 (24).   Anti-inflammatory cytokines, regulatory T cells and protective 
antibodies can help to prevent atherosclerosis.  
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                 Fig 1.4- Atherosclerosis pathway leading to thrombosis and blockage of blood flow (24).  
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Inflammation is an important factor contributing to atherosclerosis (51).  Local 
inflammation can lead to plaque instability and ultimately thrombosis.  Macrophages 
release cytokines to recruit leukocytes and increase the presence of ICAM on the cell 
surface as well as the production of NO.  NO leads to vasodilation and an increase in 
flow and leukocyte delivery, the leukocytes will adhere to adhesion molecules.  The 
circulating monocytes and leukocytes are then brought into the tissue leading to 
inflammation.  Inflammation is also accompanied by decreased bioavailability of NO 
(51).  The inflammation pathway can be seen in Figure 1.5. 
19 
 
         Figure 1.5- Inflammation pathway contributing to atherosclerosis.   
 
 Both atherosclerosis and inflammation are present in EC dysfunction and lead to 
thrombosis and/or the prevent
complications found in diabetes.
 
Blood Composition 
 Blood composition is also important to understand in normal and diabetic 
patients.  Normal blood composition consists of low
cholesterol < 100 mg/dL, high
total cholesterol < 200 mg/dL 
important antioxidant and has anti
transporting cholesterol from peripheral cells to the liver to 
(10). Normal triglyceride l
                  Table 1- LDL, HDL and total cholesterol levels as given by the National Institutes of Health.  
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Diabetic Blood Composition 
Research indicates that dyslipidemia and elevated LDL cholesterol is a major 
cause of cardiovascular disease (10, 31, 41).  These are associated with diabetic 
complications including nephropathy, retinopathy and neuropathy and high triglycerides 
(2, 31).  High LDL is considered to be 160mg/dL, low HDL is considered to be < 40 
mg/dL, high total cholesterol is considered to be > 240 mg/dL and high triglycerides are 
considered to be > 200 mg/dL (2, 31).  Once LDL levels are > 160 mg/dL 
pharmacological therapy is recommended (2).   
Dyslipidemia, which is characterized by hypercholesterolemia, 
hypertriglyceridemia and low HDL, is very prevalent in those with type II diabetes (31).  
The decrease in HDL levels are related to elevated plasma triglycerides (10).  It has also 
been found that type II diabetic patients who are obese have an even greater decrease in 
HDL levels than non-obese diabetic patients (10). Type 1 diabetic patients also often 
have dyslipidemia (31).  A study was done that showed type 1 diabetic patients were 
found to have high total cholesterol and LDL, but HDL and triglycerides were found to 
be within a normal range (31).  Glycemic control has been found to have a strong effect 
on total cholesterol, LDL and triglyceride concentrations (41).  
 
Stents in Diabetic Population 
 There are many differences in EC function between healthy patients and diabetic 
patients so it is not unusual that diabetic patients might react differently to stents. And 
diabetic patients are often times the people who are in need of stents, as diabetes is 
associated with cardiovascular disease.  1.5 million revascularization procedures are 
performed each year in the United States (20).  About 25% of patients that undergo 
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percutaneous coronary intervention have diabetes (52).  Diabetic patients have been 
shown to react differently than non-diabetic patients to implanted stents, often having an 
increase in restenosis, which is defined as > 50% diameter stenosis (52).  Diabetic 
patients also typically have smaller coronary arteries to begin with, which could be partly 
to blame for the higher restenosis rate (37).  In a study done testing multivessel stenting 
in diabetic patients it was found that there was a lower one-year survival in diabetic 
patients that were treated with either oral antigens or insulin compared with non-diabetic 
patients; about 85% in diabetic patients that were treated with oral antigens vs. 86% in 
diabetic patients who were treated in insulin, compared to 95% in non-diabetic patients 
(37).  Diabetic patients also had an increase in target lesion revascularization (TLR) (37). 
Fig. 1.6 shows the survival curve of diabetic patients treated with insulin, diabetic 
patients treated with an oral agent and non-diabetic patients.  An event-free survival was 
considered to be freedom from death, Q-wave myocardial infarction (QMI) and TLR. 
Those treated with insulin showed a trend towards an even higher revascularization rate 
and lower one-year survival rate (37).  The decreased performance in diabetic patients 
may be due to new lesions or untreated previous lesions or a decrease in the 
revascularization due to diseased coronary arteries (37).  
                   Figure 1.6- Survival curve after multivessel
                   decreased rate of event
 
 Another study evaluated patients from 16 interventional trials to determine which 
factors might be most closely related to diabetic restenosis 
metal stents were used.  Restenosis was found to increase after 6 months in diabetics 
(31.1%) as compared to non
were determined to be vessel reference diameter, stented length of vessel and 
BMI (49).  The main determinant was found to be vessel reference diameter with an 
increase of 6%, 9% and 13% above non
small-sized vessels, respectively 
 The SYNTAX (SYNergy Between PCI With TAXus and Cardia Surgery) study 
compared coronary artery bypass graft surgery (CABG) and the TAXUS Express 
paclitaxel-eluting stent (PES) in non
main and/or 3-vessel disease 
 stenting illustrating that diabetic patients have a 
-free survival after multivessel stenting  (37).   
(49).  In this study all 
-diabetics (20.6%, P< 0.001).   The predictors of restenosis 
-diabetic restinosis rates for large
(49).   
-diabetic and diabetic patients with complex left 
(9).  Revascularization in the PES group was lower among 
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the diabetic patients (49.1%) as compared to the non-diabetic patients (59.3%, P = 
0.007), however, no statistical significance was found between the revascularization rate 
of diabetic and non-diabetic patients treated with CABG (9).  Major adverse cardiac and 
cerebrovascular events (MACCE) was defined as including death, cerebrovascular 
accident (CVA) and repeat revascularization.  In one-year clinical results, MACCE was 
significantly higher in diabetic patients after PES treatment compared with non-diabetic 
patients (9).  In patients who had medically treated diabetes, PES treatment was a 
predictor for repeat revascularization but not death, CVS or MI (9).  The differences in 
diabetic patients may be due to inflammation, atherosclerosis or lesion complexity (9).   
 Another study looked to compare two different types of drug-eluting stents (19) in 
diabetic patients, paclitaxel-eluting stents (PES) and sirolimus-eluting stents (37, 50).  It 
was found that thrombosis rates were higher in both stents among insulin-treated diabetic 
patients compared to non-insulin treated patients (PES = 2.1% vs. SES = 2.8%, P = 0.74) 
(50).  The insulin-treated diabetic patients had higher rates of stent thrombosis compared 
with the non-insulin treated patients (2.5% vs. 0.6%, P = 0.005) (50).  Although, they did 
not find a statistical difference between the two different types of stents, they did find that 
insulin-treated diabetic patients are at a higher risk for thrombosis.   
 In patients with diabetes the prevalence of left main artery lesions, multivessel 
disease and CAD are increased (20).  Many studies support the finding that diabetic 
patients are more likely to suffer restenosis, death or thrombotic complications compared 
to non-diabetic patients (9, 20, 26, 37, 49, 52).  There are several physiological reasons 
that diabetic patients may fare worse.  Platelets are more likely to aggregate and there can 
be the development of hypertension, EC dysfunction, accelerated atherogenesis and 
thrombosis (20, 26).  Often times diabetic patients are found to have a smaller vessel 
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diameter and larger vessel occlusion (20).  Normally, bypass channels can form to pass 
an obstruction, however, in diabetic patients there is an impaired ability to form coronary 
collaterals (20).  Diabetic patients are also less likely to undergo remodeling of their 
coronary arteries to help compensate for an atherosclerotic build up and maintain proper 
blood flow (20).  Diabetes has a great effect on the success of a stent; the creation of a 
diabetic environment to test a stent would be beneficial to delve into what characteristics 
might reduce the rates of restenosis and thrombosis in diabetic patients.   
 
Diabetic Models 
 Due to the somewhat distinct physiology of a subject with diabetes, diabetic 
models are used to test stents before they proceed into a patient population.  Diabetic 
models help obtain important data to characterize which stents have potential in the 
clinic.  Diabetic animal models are necessary before stents can ultimately make it to the 
clinic, but the more data that can be obtained from physiologic bench top tests the better.  
There are currently many diabetic animal models, however, there are also additional 
challenges and costs associated with using animal models as opposed to further benchtop 
testing.   
Three commonly used mice models are db/db, Akita and streptozotocin (STZ) 
induced C57BL/6J.  db/db mice are genetically diabetic, they possess a genetic mutation 
of the leptin receptor and represent a model of type 2 diabetes through the presence of 
hyperglycemia, obesity, and hyperinsulemia.  Heterozygous Akita male mice represent 
type 1 diabetes through a mutation in the insulin II gene leading to hypoinsulinemia and 
eventually hyperglycemia (39).  Akita mice are very expensive and many of the offspring 
are not usable; they must be crossed with C57BL/6J mice and homozygous offspring die 
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in 12 weeks and only heterozygous males can be used (39). STZ and alloxan are 
mediated by reactive oxygen species; they can both be injected into animals to kill β-
cells, therefore rendering them unable to produce insulin, mimicking type 1 diabetes (39). 
(39). To create C57BL/6J diabetic mice, injections must be given for 5 days and then 
there is a 4 week latency period at which point some mice still do not portray a diabetic 
model.  This process requires extra time and resources (39). 
Non-obese diabetic (NOD) mice are commonly used to study type 1 diabetes.  
They spontaneously developed and display characteristics of hypercholesteremia and 
hyperglycemia.  In comparisons to humans, however, NOD mice are more often found in 
females and are more susceptible to other autoimmune diseases.  There are also some rats 
that spontaneously develop type 1 diabetes such as Biobreeding rats, DP-BB rats, 
Komeda Diabetes Prone rats, LEW.1AR1 rats and LEW.1WR1 rats (35, 50).   
 Rabbits are also commonly used to study diabetes.  A diabetic model can be 
created with an alloxan injection in New Zealand White rabbits (18). Beagle dogs have 
also been used to induce diabetes with STZ, this occurs in ten days post injection (7).  
Diabetic porcine models have been created with STZ in Chinese Guizhou minipigs (52).  
Rhesus monkey can also be used to study type 1 diabetes through STZ treatment (42).  
Total pancreatectomy is often used to induce diabetes in animal models (42).  In rhesus 
monkeys, 90% of the pancreas must be removed to cause diabetes leading to much 
greater complexity and a 7-10 day recovery period (42).  This surgery requires about 2-3 
hours and requires a professional anesthesiologist to monitor the animal (42).  The 
postoperative procedures are very similar to that of a human (42).  The use of a partial 
pancreatectomy and STZ together lead to a diabetic model after six months in rhesus 
monkeys (42).  
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Much time and effort goes in to creating animal models that can mimic diseases.  
While this is an imperative step, as animal testing creates a more physiologic 
environment than benchtop tests, more testing can be done to improve data and find the 
best candidate to pursue further testing.  The use of animals for preclinical testing 
requires more time, money and resources; more expertise and training is needed to 
properly care for the animals as well as perform surgeries.  All animal care must follow 
proper protocol and procedures in accordance with specific guidelines.  The use of a 
“diabetic” BVM could potentially help to enhance this process by being used as a 
preclinical test before stents are put into animal models to find the most promising stents.  
With a “diabetic” environment the affect of diabetes on stents can be looked at more 
closely and a stent can be designed with a higher success rate in diabetic patients.   
 
Summary and Goals of this Project 
The BVM has been created as an in vitro testing environment.  It is beneficial to 
get preliminary data regarding stent performance before animal testing is done.  The 
current BVM is designed to be as physiological as possible, although at best it represents 
a “healthy” vessel environment.  With the population of diabetics who end up with 
cardiovascular disease and due to their varying blood composition as well as the fact that 
they do not react the same to stents as non-diabetic patients, there is a need for a 
“diabetic” testing environment to be created.  
ECs are normally in a quiescent state; they are imperative for coagulation, 
leukocyte trafficking and vasomotion.  When ECs are activated as in diabetes, the 
balance is thrown off, the ECs become procoagulant, lose vaso control and this 
eventually leads to inflammation and atherosclerosis.  EC activation has also been found 
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to be correlated with ICAM-1 expression.  ICAM-1 catches circulating monocytes and 
leukocytes and brings them into the tissue leading to plaque build up.  ICAM-1 has been 
shown to be a marker present in patients with diabetes.   
The broader goal of the BVM lab is to create a diabetic environment in the BVM 
in which to test stents.  In order to facilitate this goal, the aim of this project was to create 
a protocol to test for the presence of ICAM-1, through immunohistochemistry.  This 
protocol will be obtained by testing human tonsil tissue, which is known to express 
ICAM-1.  Once this protocol can positively identify ICAM-1 using tonsil tissue, it will be 
tested on HUVECs that have been cultured in the BVM on an ePTFE scaffold.    
Eventually, different stimuli will be added to the media to up-regulate ICAM-1 leading to 
a “diabetic” environment in which stents can be tested.  This will be beneficial for 
companies to have additional preliminary benchtop tests to perform on a “diabetic” blood 
vessel mimic.  It will save time, money and resources.   
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CHAPTER 2: 
ICAM-1 
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Introduction 
Coronary artery disease is a significant factor in the death of diabetic patients 
(13).  Since diabetic patients react differently to stents than non-diabetic patients, it 
would be beneficial to have a “diabetic” environment with which to test stents.  For the 
purpose of this research a diabetic environment has been simply defined as an 
environment in which ICAM-1 is upregulated.  The first step in creating a diabetic 
environment is to be able to test if ICAM-1 is in fact present.  To do so a protocol to test 
for ICAM-1 must be created.  Once a working protocol exists, different methods can be 
investigated to upregulate ICAM-1 and tested using the protocol to see if ICAM-1 is 
upregulated.  
ICAM-1 functions in the movement of leukocytes into tissues (25).  ICAM-1 is 
only synthesized upon activation and participates in leukocyte endothelial cell adhesion 
in chronic inflammation (25).  When there is no inflammation or infection both 
leukocytes and endothelial cells are quiescent, however, if inflammatory signals are 
released, ICAM-1 is produced and expressed on the cell surface.  ICAM-1 mediates the 
binding of leukocytes by interacting with carbohydrate ligands on leukocytes.  Other 
secreted activators cause changes in the shape of the leukocytes and activate leukocyte 
integrins (such as αLβ2) causing a tighter bond between the leukocytes and ICAM-1.  
This can be seen in figure 2.1.  The leukocytes are then moved into the underlying tissue 
leading to atherosclerotic plaque build-up and narrowing of the blood vessels (25).   
Figure 2.1- ICAM pathway illustrating ICAM
 
Relevance of ICAM-
In diabetes, the activation of ECs causes the upregulation of a couple of adhesion 
molecules.  ICAM-1 was chosen to be a marker for a diabetic environment because 
research showed that ICAM
2004, looked at the ability of elevated levels of ICAM
predict the development of type 2 diabetes 
were predictors of type 2 diabetes even when corrected for BMI, family history of 
diabetes, diet score and postmenopausal hormonal use.
also found that ICAM-1 was increased ten years prior to the onset of diabetes.  It was 
concluded that elevated plasma levels of ICAM
diabetes in initially healthy women 
between insulin resistance and soluble adhesion molecule
-1 expression and leukocyte adhesion (46)
1 
-1 is a powerful predictor of type 2 diabetes.  A study d
-1, e-selectin and VCAM
(38).  It was found that e-selectin and ICAM
  Along with these results, it was 
-1 and e-selectin were predictors of type 2 
(38).  Another study analyzed the relationship 
s including ICAM
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and e-selectin (45).   Soluble adhesion molecules are in the plasma and serve as markers 
for adhesion molecules.  In this research article, it was found that ICAM-1 and e-selectin 
were inversely correlated with insulin sensitivity (45).  This study, however, also found 
that ICAM-1 was correlated with BMI and total body fat (45).   
Yet another study looked at adhesion molecules in obese hypertensive men (19).  
In this study, ICAM-1, VCAM-1 and e-selectin levels were found to be similar, not 
related to hypertension, but rather due to obesity.  Another study looked at ICAM-1, 
VCAM-1 and selectins in people who were obese, hypertensive or type 1 diabetic (22).  
There was an increase of ICAM-1, VCAM-1 and e-selectin in children and adults who 
were type 1 diabetic, hypertensive or obese (22).  In type 1 diabetic children, the levels of 
ICAM-1 and e-selectin were increased; VCAM-1 and ICAM-1 were dependent upon type 
1 diabetic children’s triglyceride levels (22).  Children who were genetically predisposed 
to diabetes had an increased level of ICAM-1.  There was also an association of ICAM-1 
with the risk of myocardial infarction (22). It was concluded that endothelial activation 
was mostly found to be due to ICAM-1 and e-selectin (22).   
 
ICAM-1 Analysis Techniques 
The studies above all support the use of ICAM-1 as a predictor of diabetes, and 
thus ICAM-1 was chosen as a marker for a diabetic environment in this project.  There 
are a couple of different ways that ICAM-1 can be measured- protein analysis, mRNA 
analysis, immunohistochemistry and immunfluorescence.  All of these techniques could 
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possibly show if ICAM-1 is present or being upregulated.  Certain procedures are better 
for certain applications.  
Protein expression of ICAM-1 can be done using an array biochip (14).  This 
method allows for many different proteins to be analyzed. Different DNA binding 
sequences or antibodies can be placed onto the biochip to detect proteins in the solution.  
In one study, researchers took blood samples and kept them at -70°C and then measured 
for different adhesion molecules in the plasma (14).  This is a good method to use when 
there are cells in a solution that must be analyzed.  
Flow cytometry is often used to count populations of interest.  It can sort particles 
based on their properties.  Flow cytometry is often used in immunofluorescence.  
Detectors can pick up the fluctuations in fluorescent emission peaks to determine the 
amount of fluorescence present (27).  In a published study, HUVECs were enzymatically 
isolated and treated with different concentrations of D-glucose; the effect of D-glucose on 
inflammation was analyzed.  The HUVECs were first trypsinized and then put in a 
blocking solution followed by a rinse in PBS (8).  Next the cells were suspended in the 
primary antibody and then the primary antibody was detected through the use of a 
secondary antibody and the flow cytometer can measure the fluorescent intensity (8).  
The researchers found that increased extracellular D-glucose did not cause ICAM-1 
upregulation (8).  Another study, that looked at the use of a mushroom to induce ICAM-
1, used flow cytometry to analyze the ICAM-1 protein on the cell surface, and 
polymerase chain reaction (PCR) to analyze the mRNA level of ICAM-1 (29).  To 
measure the protein expression on the cell surface, the cells were stained with anti-human 
ICAM-1 antibody conjugated with phycoerythrin.  The cells were then analyzed with a 
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flow cytometer and the data displayed the fluorescent intensities. In PCR, part of the 
DNA will be amplified by going through denaturation and replication cycles; 
complementary DNA is synthesized to allow for selective replication.  mRNA was 
analyzed to ensure that an increase in mRNA levels of ICAM-1 was correlated to an 
increase in protein expression levels of ICAM-1. 
Immunofluorescence is another very common technique to analyze the expression 
of ICAM-1 levels.  One study looked at the upregulation of ICAM-1 due to 
lipopolysaccharide (LPS) (43).  To use this method, samples were embed in tissue-
freezing media and frozen at -70°C.  A cryotome was used to cut sections and the 
samples were then dried at room temperature for two hours.  The sections were then 
treated with a 30% methanol/ 70% acetone mixture (43).  The sections were next fixed in 
paraformaldehyde, washed in PBS (43).  They were then incubated in 10% donkey serum 
in PBS for 30 minutes to block nonspecific binding sites (43).  Next was an incubation in 
the primary antibody at a 1:200 dilution for one hour (43).  Then the samples were 
washed with PBS and incubated in Cy3-labeled donkey anti-rat IgG at a 1:250 dilution 
for 45 minutes.  The samples were then washed with PBS and counterstained with 
fluorescein-labeled wheat germ agglutinin and bisbenzamide.  Finally, the samples were 
coverslipped (43).  This method allowed researchers to see that there was an increase in 
ICAM-1 expression due to LPS (43).  In another study the effect of sustained hypoxia on 
ICAM-1 was analyzed (12).  To do so, rats were exposed to hypobaric hypoxia and then 
the lung tissue was embedded.  The protein level of ICAM-1 was found to increase 
through immunofluorescent staining.  Immunofluorescent staining is a very useful way to 
determine if a certain protein is present.  If the protein is present it will be tagged by the 
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primary antibody and following reagents leading to the expression of fluorescence, which 
can easily be seen.   
Immunohistochemistry (IHC) is also frequently used to measure ICAM-1 levels.  
To perform IHC, the samples are fixed, dehydrated and then embeded in paraffin wax 
(8). Frozen tissue sections and tissue culture cells can also be used as samples (44).  If the 
samples are in paraffin wax, they can be sectioned and then stained with a primary 
antibody, secondary antibody, AB enzyme reagent, followed by peroxidase substrate 
(44).  One study analyzed the simultaneous expression of ICAM-1, VCAM-1 and 
vascular endothelial growth factor (VEGF) in diabetic fibrovascular membranes using 
IHC (28).  They used an anti-human ICAM-1 antibody.  These samples were also 
embedded in paraffin wax (28).  The first step after sectioning the samples was to 
rehydrate the samples in alcohols, incubate them in hydrogen peroxide, perform an 
antigen retrieval step, incubate in a blocking solution, leave them overnight at 4°C with 
the primary antibody, wash them in PBS, incubate with biotinylated secondary antibody 
for 60 min, wash in PBS, and finally incubate in streptavidin horseradish peroxidase and 
chromogen (28).   This method allowed researchers to find coexpression of ICAM-1, 
VCAM-1 and VEGF in most of the fibrovascular membranes they looked at.  ICAM-1 
was the most common, it was in eight of nine membranes (28).  IHC is very similar to 
immunofluoresence except instead of being tagged with fluorescence, a brown staining 
will be shown if the protein being tagged is present.   
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ICAM-1 Expression 
The specific aim of this project is to create a protocol to determine if a “diabetic” 
environment is created in the BVM to test stents by using ICAM-1 as a marker for 
diabetes.  In this project, IHC was the first method used.  Tonsil tissue was used as a 
positive control because research has shown that tonsil expresses adhesion molecules 
including ICAM-1 (17).  A lot of positive staining is typically seen in the high endothelial 
venules (HEV) in the parafollicular regions, and lower border regions of the reticulated 
epithelium.  ICAM-1 can also be seen on epithelial cells of the crypts (40).  The palatine 
tonsil has openings called crypts that are lined with reticulated epithelium, which 
contains epithelial cells, lymphocytes and endothelial cells- all of which stained positive 
for ICAM-1 (30).  Figure 2.2 below shows human palatine tonsils stained for ICAM-1; 
the HEVs of the parafollicular region can be seen as PF, the cryptal epithelium is labeled 
CE, and the follicular region (F) does not stain positive for ICAM-1 (40).  Germinal 
centers of the human tonsil also have a high uniform expression of ICAM-1 (23).   The 
protocol used in Figure 2.2 consisted of fixing the palatine tonsil in paraformaldehyde 
and then frozen in liquid nitrogen (40).  30um sections were incubated at 4°C for 48 
hours in the primary antibody (anti-ICAM-1).  They were the incubated with goat-anti-
mouse IgG, silver-enhanced, dehydrated, immersed in propylene oxide, infiltrated with 
propylene oxide and resin and then embedded in TAAB-resin (40).  Figure 2.2 shows 
what might be expected to stain positive for ICAM-1. 
                                                      
                                                      
 
H&E 
Since tonsil tissue is known to express ICAM
to create an ICAM-1 protocol.  Before starting IHC, H&E staining was done to 
characterize the tissue.  Hematoxylin will stain nuclei blue; the eosin stains cytoplasm 
pink.  The first H&E protocol can be seen below.  It was verified that this was tonsil 
tissue by looking at the H&E slides.  A microtome was used to make sections of 6um.  
Pants, closed toed shoes and gloves were worn at all times.  All steps were performed in 
the fume hood, and slides were allowed to dry for 48 hours before viewing in the 
microscope. 
Protocol #1: H&E Staining of human tonsil tissue. October 18, 2009.
Purpose: See the structure and morphology of the tonsil tissue.
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.  
Process: 
 
Figure 2.2- Immuno-electron-microscopic  
staining of ICAM-1 on human palatine tonsils (40).   
-1 it was used as a positive control 
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1) 3 minutes in xylene 
2) 3 minutes in xylene 
3) 3 minutes in xylene 
4) 2 minutes in 100% EtOH 
5) 2 minutes in 100% EtOH 
6) 2 minutes in 95% EtOH 
7) 1 minute air dry 
8) 4 minutes in hematoxylin 
9) 1 minute in distilled H2O 
10) 30-45 seconds in clarifier 
11)  1 minute in distilled H2O 
12) I minute in bluing 
13) 1 minute in distilled H2O 
14) 1 minute in 95% EtOH 
15) 1 minute 30 sconds in eosin 
16) 1 minute in 100% EtOH 
17) 1 minute in 100% EtOH 
18) 1 minute in 100% EtOH 
19) 3 minutes in xylene 
20) 3 minutes in xylene 
21) 3 minutes in xylene 
This first protocol created tissue samples that were dark purple so the hematoxylin 
time was decreased.  The next protocol was changed from 4 minutes in hematoxylin to 3 
minutes in hematoxylin.  This was better, but still a little dark.  H&E staining was done 
one more time with 2:30 minutes in hematoxylin and the samples were much easier to 
see.  The last protocol with hematoxylin time at 2:30 minutes was accepted.  Images of 
the tonsil tissue at all of the different hematoxylin times can be seen below.   
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        Figure 2.3- Tonsil tissue in hematoxylin for 4 minutes  
 
 
                                   Figure 2.4- Tonsil tissue in hematoxylin for 3 minutes  
 
                                      Figure 2.5- Tonsil tissue in hematoxylin for 2:30 minutes 
Final Protocol: H&E Staining of human tonsil tissue- Protocol Accepted. January 9, 
2010. 
Purpose: See the structure and morphology of the tonsil tissue. 
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.   
Process: 
1) 3 minutes in xylene 
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2) 3 minutes in xylene 
3) 3 minutes in xylene 
4) 2 minutes in 100% EtOH 
5) 2 minutes in 100% EtOH 
6) 2 minutes in 95% EtOH 
7) 1 minute air dry 
8) 2:30 minutes in hematoxylin 
9) 1 minute in distilled H2O 
10) 30-45 seconds in clarifier 
11)  1 minute in distilled H2O 
12) I minute in bluing 
13) 1 minute in distilled H2O 
14) 1 minute in 95% EtOH 
15) 1 minute 30 sconds in eosin 
16) 1 minute in 100% EtOH 
17) 1 minute in 100% EtOH 
18) 1 minute in 100% EtOH 
19) 3 minutes in xylene 
20) 3 minutes in xylene 
21) 3 minutes in xylene 
 
 
Immunohistochemistry 
Next an ICAM-1 IHC protocol was worked on.  Anti-ICAM-1 antibody, catalog 
number sc-107 was purchased from Santa Cruz Biotechnology along with mouse ABC 
system sc-2017.  The ABC system comes with suggested instructions ranging in times 
and concentrations.  Protocol #1 is shown below.  Before the protocol is begun, the 
samples are sectioned at 6um.  Control slides were incubated in PBS while the 
experimental slides were incubated with the primary antibody.  A Tupperware was used 
as a humidified chamber, to do so a paper towel was wetted and placed on the bottom of 
the tupperware.  The slides then sat on the paper towel.  To aspirate off reagents, one 
slide was aspirated, the new reagent was put on and then the next slide was aspirated and 
then a new reagent put on.  This continued until all the slides were incubating in the new 
reagent and prevented the slides from drying out.  For safety precautions closed toed 
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shoes, long pants and gloves should be worn at all times.  The AB enzyme reagent should 
be mixed in the hood.  All reagents must be made fresh and if extras are left, disposed of 
in the waste container.   
Protocol #1: Immunohistochemistry analysis of human tonsil tissue using ICAM-1 
antibody to create a positive control.  October 13, 2009. 
Purpose: To stain human tonsil tissue for ICAM for a positive control. 
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.  ICAM-1 antibody 
from Santa Cruz Biotechnology.  Mouse ABC kit.  Control: 09-176-2 
Process: 
1) Mix PBS as per directions on the packet 
 one pouch PBS, pH 7.4 mixed with 1L distilled H2O 
2) incubate slides with two changes of PBS for 5 minutes 
3) Prepare primary antibody- 1µg/ml 
• Pipette 5 µl ICAM antibody 
• Pipette 0.995 ml blocking serum 
4) incubate slides with primary antibody prepared above for 30 minutes 
5) Wash with 3 changes of PBS for five minutes each 
6) Prepare secondary antibody (green bottle) as follows 
• 75µl normal blocking serum 
• 5ml PBS 
• 25µl secondary antibody stock 
7) incubate with newly prepared secondary antibody for 30 minutes 
8) Prepare antibody enzyme reagent in hood 
• 50µl advin 
• 50µl biotinylated HRP 
• 2.5ml PBS 
9) Wash with 3 changes of PBS for 5 minutes each 
10) incubate sections with antibody enzyme reagent for 30 minutes 
11) Wash with three changes of PBS for 5 minutes each 
12) Prepare peroxidase substrate 
• 1.6ml distilled H2O 
• 5 drops 10x substrate buffer 
• 1 drop 50x DAB chromogen 
• 1 drop 50x peroxidase substrate 
13) incubate peroxidase substrate for 5 minutes 
14) Wash in distilled water for 5 minutes 
15) incubate in 95% ethanol twice for ten seconds each 
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16) incubate in 100% ethanol twice for ten seconds each 
17) incubate in xylene three times for ten seconds each 
18) Add 1-2 drops of mounting medium and cover. 
19) Let dry for 48 hours 
 
This protocol did not show any positive staining of ICAM-1, endogenous staining 
were seen in the control and the experimental samples.  The next time IHC was 
attempted, the concentration of ICAM-1 antibody was changed from 1ug/ml to 3ug/ml.  
This did not show any positive staining either.  The ICAM-1 antibody was then increased 
to 5ug/ml again resulting in no positive staining.  The next protocol will be considered 
protocol #2.  This protocol kept the ICAM-1 antibody concentration at 5mg/ml but added 
dehydration steps at the beginning, added the pap pen and added an hour incubation in 
normal blocking serum.  The pap pen creates a hydrophobic barrier so the solutions will 
stay over the tissue section; the blocking serum will help to block endogenous staining.   
Protocol #2: Immunohistochemistry analysis of human tonsil tissue using ICAM-1 
antibody to create a positive control.  February 20, 2010. 
Purpose: To stain human tonsil tissue for ICAM for a positive control. 
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.  ICAM-1 antibody 
from Santa Cruz Biotechnology.  Mouse ABC kit.  Control: 09-18A, 09-184D 
Process: 
1) Mix PBS as per directions on the packet 
 One pouch PBS, pH 7.4 mixed with 1L distilled H2O 
2) incubate slides with two changes of PBS for 5 minutes 
3) Wash slides in xylene for 5 minutes 
4) Wash slides in xylene for 5 minutes 
5) Prepare blocking serum 
• 75 µl normal blocking serum 
• 5 ml PBS 
• Remove 0.990 ml to add to ICAM-1 antibody 
• Save some to incubate control slide in blocking serum 
5) Wash slides in 100% ethanol for 1 minute 
6) Wash slides in 100% ethanol for 1 minute 
7) Wash slides in 95% ethanol for 1 minute 
8) Remove slides, let them dry a little and add pap pen 
9) incubate slides with blocking serum for 1 hour 
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• Suction reagent after 1 hour, one slide at a time adding new reagent to each to 
prevent drying out 
10) Prepare primary antibody- 5 µg/ml 30-45 minutes into step 8 
• Pipette 25 µl ICAM antibody 
• Pipette 0.975 ml blocking serum 
11) incubate slides with primary antibody prepared above for 30 minutes 
12) Wash with 3 changes of PBS for five minutes each 
13) Prepare secondary antibody (green bottle) as follows 
• 75µl normal blocking serum 
• 5ml PBS 
• 25µl secondary antibody stock 
14) incubate with newly prepared secondary antibody for 30 minutes 
15) Prepare antibody enzyme reagent in hood 
• 50µl advin 
• 50µl biotinylated HRP 
• 2.5ml PBS 
16) Wash with 3 changes of PBS for 5 minutes each 
17) incubate sections with antibody enzyme reagent for 30 minutes 
18) Wash with three changes of PBS for 5 minutes each 
19) Prepare peroxidase substrate 
• 1.6ml distilled H2O 
• 5 drops 10x substrate buffer 
• 1 drop 50x DAB chromogen 
• 1 drop 50x peroxidase substrate 
20) incubate peroxidase substrate for 5 minutes 
21) Wash in distilled water for 5 minutes 
22) incubate in 95% ethanol twice for ten seconds each 
23) incubate in 100% ethanol twice for ten seconds each 
24) incubate in xylene three times for ten seconds each 
25) Add 1-2 drops of mounting medium and cover. 
26) Let dry for 48 hours 
 
This protocol was not successful.  The next IHC protocol removed the PBS step 
before the slides were put into xylene for the first time, and added a hydrogen peroxide 
step for five minutes after the pap pen was applied to the samples.  This was not 
successful.  The next protocol was done with some of the samples in hydrogen peroxide 
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and some without hydrogen peroxide.  When the hydrogen peroxide is used, less 
endogenous staining is seen in the tonsil tissue, however, there is still endogenous 
staining in both the samples treated with ICAM-1 antibody and those without.  IHC 
images from this protocol can be seen in Figure 2.6 and 2.7.  The tonsil tissue was 
washed in PBS by putting them in dishes in some cases and pipetting PBS over the 
samples in other times.  Neither of these techniques made a difference.  The next time 
IHC was attempted, the hydrogen peroxide step was omitted and the samples were 
incubated with the primary antibody overnight at 4°C instead of for 30 minutes at room 
temperature.  The samples were also incubated in the peroxidase substrate for ten 
minutes, as opposed to five minutes.  The controls were left in PBS overnight; still no 
positive ICAM-1 staining was seen.   
 
 
                                    Figure 2.6- Tonsil tissue without hydrogen peroxide  
 
 
45 
 
                                    
                                   Figure 2.7- Tonsil tissue with hydrogen peroxide 
 
The next trial included an antigen retrieval step, increased the dehydration steps, 
and did not have a hydrogen peroxide step.  Sometimes when samples are embedded in 
paraffin wax, the wax can block the antigen from binding to the primary antibody; using 
an antigen retrieval step can unmask the antigen.  This heat treatment step was done by 
incubating the samples in a 0.05% saponin solution.  Again, no positive staining was 
seen; both the control and the experimental slides showed brown staining.  The next 
protocol included the same antigen retrieval step with saponin, but also included a 
hydrogen peroxide step.  Again, no positive staining was found.  For the next protocol the 
hydrogen peroxide was found to have been expired so it was omitted and sodium citrate 
was used for an antigen retrieval step.  Sodium citrate was ordered from Santa Cruz 
Biotechnology, sc-203383.  This protocol will be considered protocol #3.   
Protocol #3: Immunohistochemistry analysis of human tonsil tissue using ICAM-1 
antibody to create a positive control.  April 17, 2010. 
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Purpose: To stain human tonsil tissue for ICAM for a positive control. 
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.  ICAM-1 antibody 
from Santa Cruz Biotechnology.  Mouse ABC kit.  Control: 09-180B, 09-183B 
Process: 
1) incubate slides in the oven for 10 minutes 
2) Let slides cool for 5 minutes 
3) Wash slides in xylene for 5 minutes 
4) Mix PBS as per directions on the packet 
 One pouch PBS, pH 7.4 mixed with 1L distilled H2O 
5) Wash slides in xylene for 5 minutes 
6) Wash slides in xylene for 5 minutes 
7) Wash slides in 100% ethanol for 10 minutes 
8) Wash slides in 100% ethanol for 10 minutes 
9) Wash slides in 95% ethanol for 10 minutes 
10) Wash slides in 95% ethanol for 10 minutes 
11) Heat 10mM sodium citrate buffer, pH 6.0 
• 95°C 
12) incubate slides in distilled water for 1 minute with stirring 
13) incubate slides in 95°C sodium citrate buffer for 5 minutes 
• use incubator to keep sodium citrate hot 
14) Heat new 10mM sodium citrate buffer for 5 minutes 
15) incubate slides in 95°C sodium citrate buffer for 5 minutes 
• use incubator to keep sodium citrate hot 
16) Allow slides to cool in sodium citrate buffer for 20 minutes 
17) Wash in distilled H2O three times for 2 minutes each 
18) Add pap pen to samples 
19) Prepare blocking serum 
• 75 µl normal blocking serum 
• 5 ml PBS 
• Remove 0.975 ml to add to ICAM-1 antibody 
• Save some to incubate control slide in blocking serum 
20) incubate slides with blocking serum for 1 hour 
• Suction reagent after 1 hour, one slide at a time adding new reagent to each to 
prevent drying out 
21) Prepare primary antibody- 5 µg/ml 30-45 minutes into step 8 
• Pipette 25 µl ICAM-1 antibody 
• Pipette 0.975 ml blocking serum 
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22) incubate slides with primary antibody prepared above for 30 minutes at room 
temperature 
23) Wash with 3 changes of PBS for five minutes each 
24) Prepare secondary antibody (green bottle) as follows 
• 75µl normal blocking serum 
• 5ml PBS 
• 25µl secondary antibody stock 
25) incubate with newly prepared secondary antibody for 30 minutes 
26) Prepare antibody enzyme reagent in hood- must sit for 30 minutes 
• 50µl advin 
• 50µl biotinylated HRP 
• 2.5ml PBS 
27) Wash with 3 changes of PBS for 5 minutes each 
28) incubate sections with antibody enzyme reagent for 30 minutes 
29) Wash with three changes of PBS for 5 minutes each 
30) Prepare peroxidase substrate 
• 1.6ml distilled H2O 
• 5 drops 10x substrate buffer 
• 1 drop 50x DAB chromogen 
• 1 drop 50x peroxidase substrate 
31) incubate peroxidase substrate for 5 minutes 
32) Wash in distilled water for 5 minutes 
33) incubate in 95% ethanol twice for ten seconds each 
34) incubate in 100% ethanol twice for ten seconds each 
35) incubate in xylene three times for ten seconds each 
36) Add 1-2 drops of mounting medium and cover 
37) Let dry for 48 hours 
 
In this protocol, the sodium citrate was heated in the microwave and then put into 
the incubator to keep warm.  However, the incubator only kept the sodium citrate at 
80°C, which is much lower than the recommended 95°C.  In the next try, sodium citrate 
was used (still did not reach the desired temperature) and the blocking serum incubation 
for one hour was omitted.  In the next protocol the sodium citrate was heated in a beaker 
(from VWR, which has a heat rating of 400°C) on a hot plate and the solution was kept at 
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95°C.  The hydrogen peroxide was also used.  It was later found that the blocking serum 
used in protocol #3 and the following protocols was mouse serum and should have been 
goat serum.  None of these protocols showed any positive ICAM-1 staining, there was a 
lot of endogenous staining seen on all of the slides.   
 
Immunofluorescence 
Due to the high amount of endogenous staining seen, it was decided to switch to 
immunofluorescence.  Ultra cruz mounting medium (sc-24941), goat anti-mouse IgG-
FITC (sc-2010), and goat blocking serum (sc-2043) were ordered from Santa Cruz 
Biotechnology.  The initial immunofluorescence protocol will be considered protocol #1 
and can be seen below.  Tonsil tissue was still used for the positive control.   
Protocol #1: Immunofluorescent analysis of human tonsil tissue using anti-ICAM-1 
antibody to create a positive control.  May 9, 2010. 
Purpose: To stain human tonsil tissue for ICAM for a positive control. 
Materials: Paraffin embedded tonsil tissue obtained in October, 2009.  ICAM-1 antibody 
from Santa Cruz Biotechnology.  Goat anti-mouse IgG-FITC.  Goat blocking serum.  
Control: 09-180C, 09-184C. 
Process: 
1) incubate slides in the oven for 10 minutes 
2) Let slides cool for 5 minutes 
3) Wash slides in xylene for 5 minutes 
4) Mix PBS as per directions on the packet 
• One pouch PBS, pH 7.4 mixed with 1L distilled H2O 
5) Wash slides in xylene for 5 minutes 
6) Wash slides in xylene for 5 minutes 
7) Wash slides in 100% ethanol for 10 minutes 
8) Heat 10mM sodium citrate buffer, pH 6.0 in a 1 L VWR beaker on a hot plate until it 
boils 
• 95°C 
9) Wash slides in 100% ethanol for 10 minutes 
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10) Wash slides in 95% ethanol for 10 minutes 
11) Wash slides in 95% ethanol for 10 minutes 
12) incubate slides in distilled water for 1 minute with stirring 
13) incubate slides in 95°C sodium citrate buffer for 5 minutes 
• use hot plate to keep sodium citrate hot 
• put slide rack in 1 L VWR beaker 
14) Top 10mM sodium citrate buffer to 500 ml in 1 L VWR beaker 
15) incubate slides in 95°C sodium citrate buffer for 5 minutes 
• use hot plate to keep sodium citrate hot 
16) Allow slides to cool in sodium citrate buffer for 20 minutes 
17) Wash in distilled H2O three times for 2 minutes each 
18) Prepare 10% normal blocking serum- goat 
• 0.25 ml normal blocking serum (goat) 
• 2.25 ml PBS 
• This can be replaced with bovine serum albumin 
19) Add pap pen to samples 
20) incubate in normal blocking serum for 20 minutes 
21) Wash with PBS- 5 minutes 
22) Prepare primary antibody 
• 15 µl normal blocking serum 
• 0.985 ml PBS 
• 20 µl anti-ICAM antibody  1:50 dilution 
• can try 0.5- 5.0µg/ml 
23) incubate slides with primary antibody for 1 hour 
• Suction reagent after 1 hour, one slide at a time adding new reagant to each to 
prevent drying out 
24) Wash with 3 changes of PBS for five minutes each 
25) Prepare fluorochrome-conjugated secondary antibody 
• 30 µl normal blocking serum 
• 1.97 ml PBS 
• 15 µl secondary antibody 
• Can try 1.0- 5.0µg/ml (this one is 3µg/ml) 
• Can mix normal blocking serum to be 1.5% (now) to 3% 
26) incubate with newly prepared secondary antibody for 45 minutes 
• Must be in a dark chamber 
27) Wash with 3 changes of PBS for 5 minutes each  
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28) Mount coverslip with aqueous mounting medium or 90% glycerol in PBS 
 
 After protocol #1, background staining was seen in the control and experimental 
slides.  Images from protocol #1 can be seen in figure 2.8 and 2.9.  In the next protocol, 
the FITC concentration was adjusted from a 3mg/ml dilution to a 1ug/ml dilution (1:500).  
It was also found that some of the beakers do not fit the slide racks- even beakers with the 
same catalog number.  From then on the beaker was tested with the slide rack to ensure 
the slide rack will fit into the beaker before sodium citrate was added to the beaker and 
heated.  The next protocol diluted the FITC even more to a 1:1000 dilution.  Still 
background staining was seen, as shown in Figures 2.10 and 2.11.  There is nothing 
known in tonsil tissue that the secondary tissue should be binding too.  Both tonsil tissue 
and the reagents from Santa Cruz Biotechnology have been cited in research articles.  To 
test for background staining both a different species secondary antibody was tried and 
culturing HUVECs as opposed to using tonsil tissue was tried.  This resulted in 
background staining still being seen.  Since the background staining is seen with both 
secondary antibodies, it is likely that the background staining could be due to the sample 
rather than the reagents.   
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                                         Figure 2.8- Immunofluorescent image of control (w/o primary antibody)                    
 
 
 
     
                                   Figure 2.9- Immunofluorescent image of experimental tissue, protocol #1 
 
 
                                        Figure 2.10- Immunofluorescent image of control (w/o primary antibody),  
                                        1:1000 FITC dilution    
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           Figure 2.11- Immunofluorescent image of experimental tissue,  
                                        1:1000 FITC dilution 
 
The immunofluorescent protocol on HUVECs can be seen below. 
Protocol #2: Immunofluorescent analysis of HUVECS using anti-ICAM-1 antibody to 
create a positive control.  May 20, 2010. 
Purpose: To stain human tonsil tissue for ICAM for a positive control. 
Materials: HUVECs p9.  ICAM-1 antibody from Santa Cruz Biotechnology.  Goat anti-
mouse IgG-FITC.  Goat blocking serum.  Dextran.  Control: cultured in DMEM, not 
dextran 
Process: 
1) Make dextran: 10%, 20%, 30% (and DMEM = control) 
• 1ml = 1 gram 
• 0.63 grams dextran: 9.37 ml DMEDM 
• 1.4 grams dextran: 8.6 ml DMEM 
• 1.75 grams dextran: 8.25 ml DMEM 
2) Culture cells with dextran for 24 hours 
3) Fix cells: 5 minutes in -10º C methanol, air dry 
4) Wash cells in three changes of PBS 
5) Mix PBS as per directions on the packet 
• One pouch PBS, pH 7.4 mixed with 1L distilled H2O 
6) Prepare 10% normal blocking serum- goat 
• 0.20 ml normal blocking serum (goat) 
• 1.8 ml PBS 
• This can be replaced with bovine serum albumin 
7) Incubate in normal blocking serum for 20 minutes 
8) Wash with PBS- 5 minutes 
9) Prepare primary antibody 
• 15 µl normal blocking serum 
• 0.985 ml PBS 
• 20 µl anti-ICAM antibody  1:50 dilution 
• can try 0.5- 5.0µg/ml 
10) Incubate slides with primary antibody for 1 hour 
• Suction reagant after 1 hour, one slide at a time adding new reagant to each to 
prevent drying out 
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11) Wash with 3 changes of PBS for five minutes each 
12) Prepare fluorochrome-conjugated secondary antibody (recommend 1:500 dilution) 
this is 1:1000 dilution 
• 60 µl normal blocking serum 
• 1.94 ml PBS 
• 2 µl secondary antibody 
• Can try 1.0- 5.0µg/ml  
• Can mix normal blocking serum to be 1.5% to 3% (now) 
13) Incubate with newly prepared secondary antibody for 45 minutes 
• Must be in a dark chamber 
14) Wash with 3 changes of PBS for 5 minutes each  
15) Mount coverslip with aqueous mounting medium or 90% glycerol in PBS. 
 
 When the HUVECs were imaged, it was found that there were no cells attached to 
the four well plates.  The most likely reason is due to the cells not properly being fixed.  
The temperature of the methanol was not measured before it was put onto the cells, 
however, the methanol was left in the freezer for 24 hours before being used.  The 
methanol must also be allowed some time to air dry without drying the cells out- this 
could have needed to air dry for longer.   
 The immunofluorescent protocol used with the donkey anti-mouse IgG-FITC can 
be seen below.  There were some changes in this protocol compared to protocol #2.  The 
PBS wash after the incubation with the normal blocking serum was changed from 5 
minutes to one minute.  The control slides were incubated with a 10% normal blocking 
serum in PBS instead of just PBS.  After the incubation with FITC there were three PBS 
washes added, then three five minute incubations and then three rinses before being 
coverslipped.   
Protocol #3: Immunofluorescent analysis of human tonsil tissue using anti-ICAM-1 
antibody to create a positive control.  May 22, 2010. 
Purpose: To stain human tonsil tissue for ICAM-1 for a positive control. 
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Materials: Paraffin embedded tonsil tissue obtained in October, 2009.  HUVECS on 
ePTFE embed in paraffin wax.  ICAM-1 antibody from Santa Cruz Biotechnology.  
Donkey anti-mouse IgG-FITC.  Donkey blocking serum.  Control: 09-178C 
Process: 
1) Incubate slides in the oven for 10 minutes 
2) Let slides cool for 5 minutes 
3) Wash slides in xylene for 5 minutes 
4) Mix PBS as per directions on the packet 
• One pouch PBS, pH 7.4 mixed with 1L distilled H2O 
5) Wash slides in xylene for 5 minutes 
6) Wash slides in xylene for 5 minutes 
7) Wash slides in 100% ethanol for 10 minutes 
8) Heat 10mM sodium citrate buffer, pH 6.0 in a 1 L VWR beaker on a hot plate until it 
boils 
• 95°C 
9) Wash slides in 100% ethanol for 10 minutes 
10) Wash slides in 95% ethanol for 10 minutes 
11) Wash slides in 95% ethanol for 10 minutes 
12) Incubate slides in distilled water for 1 minute with stirring 
13) Incubate slides in 95°C sodium citrate buffer for 5 minutes 
• use hot plate to keep sodium citrate hot 
• put slide rack in 1 L VWR beaker 
14) Top 10mM sodium citrate buffer to 500 ml in 1 L VWR beaker 
15) Incubate slides in 95°C sodium citrate buffer for 5 minutes 
• use hot plate to keep sodium citrate hot 
16) Allow slides to cool in sodium citrate buffer for 20 minutes 
17) Wash in distilled H2O three times for 2 minutes each 
18) Prepare 10% normal blocking serum- donkey 
• 0.20 ml normal blocking serum (donkey) 
• 1.8 ml PBS 
• This can be replaced with bovine serum albumin 
19) Add pap pen to samples 
20) Incubate in normal blocking serum for 20 minutes 
21) Wash with PBS- 5 minutes 
22) Prepare primary antibody 
• 15 µl normal blocking serum 
• 0.985 ml PBS 
• 20 µl anit-ICAM-1 antibody  1:50 dilution 
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• can try 0.5- 5.0µg/ml 
23) Incubate slides with primary antibody for 1 hour 
• Suction reagant after 1 hour, one slide at a time adding new reagant to each to 
prevent drying out 
24) Wash with 3 changes of PBS for five minutes each 
25) Prepare fluorochrome-conjugated secondary antibody (recommend 1:500 dilution) 
this is 1:1000 dilution 
• 60 µl normal blocking serum 
• 1.94 ml PBS 
• 2 µl secondary antibody 
• Can try 1.0- 5.0µg/ml  
• Can mix normal blocking serum to be 1.5% to 3% (now) 
26) Incubate with newly prepared secondary antibody for 45 minutes 
• Must be in a dark chamber 
27) Wash with 3 changes of PBS for 5 minutes each  
28) Mount coverslip with aqueous mounting medium or 90% glycerol in PBS 
 
 During this protocol, the HUVECs on ePTFE all fell off of the slide during the 
heat treatment step.  To retry the HUVECs without the heat treatment step, protocol #3 
was adhered to with the omittance of the heat treatment step.  The tonsil tissue in 
protocol#3 still showed background staining.  It was found that the hydrophobic barrier 
pen that is used to keep the reagents over the sample fluoresces.  Vector Laboratories was 
contacted and it was stated that the pen and its residue does fluoresce, however, this 
should not affect the tissue samples.  Images of this can be seen in figure 2.12.  The 
fluorescing of the tonsil tissue does not look like residue of the pen; it looks like circular 
cells and the cells are fixed before they come into contact with the pen so their expression 
will not be altered.   
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                                     Figure 2.12- Fluorescence of the hydrophobic barrier pen. 
 
Summary  
After protocol #3, due to the continuing result of non-specific staining, the tonsil 
tissue was further analyzed to try to figure out why there is background staining. Even 
using both IHC and immunofluorescence, background staining was seen.  Concentrations 
of reagents were changed, incubation times were changed, and secondary antibodies were 
changed.  None of these attempts lead to successful identification of ICAM-1 on the 
tonsil tissue.   
The tonsil tissue, received from Central Coast Pathology was most likely fixed in 
formalin.  The time that the samples are in formalin can greatly increase the background 
staining.  Since the tonsil tissue was received already fixed, it is unknown how long they 
were in formalin.  Therefore, further methods need to be analyzed to create a positive 
ICAM-1 protocol using tissue that can be fixed on the Cal Poly campus to ensure proper 
fixation for use with IHC and immunofluorescence.   
On the Santa Cruz Biotechnology website, research articles are listed that use the 
same ICAM-1 antibody.  Dr. Hsinyu Lee was contacted about the article 
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“Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-
{kappa}B-dependent mechanism Lee” (34) in which immunofluorescence was used. Dr. 
Anil Kumar Bhunia was also contacted about his research article "Lactosylceramide 
Mediates Tumor Necrosis Factor-induced Intercellular Adhesion Molecule-1 (ICAM-1) 
Expression and the Adhesion of Neutrophil in Human Umbilical Vein Endothelial Cells,” 
in this article immunofluorescence and IHC was used.   
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CHAPTER 3: 
SUMMARY AND CONCLUDING REMARKS 
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Summary 
 This project worked towards the goal of creating an ICAM-1 protocol to 
be used in creating a “diabetic” environment.  In summary, a “diabetic” environment in 
which to test stents would be very beneficial.  Diabetes is marked by endothelial 
dysfunction leading to the upregulation of ICAM-1, procoagulation, inflammation and 
decreased vasodilation.  ICAM-1 causes leukocytes to migrate into the vessel leading to 
an atherosclerotic plaque build up, which can rupture and form a clot, or impede blood 
flow.  It is widely accepted that diabetic patients react differently to stents than non-
diabetic patients; this is thought to be due to inflammation, lesion complexity and 
atherosclerosis, all commonly found in diabetic patients (9).  With 6% of the population 
in the US having diabetes, and a high rate of cardiovascular disease in diabetics, a better 
treatment is imperative (16).  ICAM-1 is an appropriate marker for diabetes and can be 
used to measure if a “diabetic” environment has been created in the BVM.  Studies have 
shown that elevated plasma levels of ICAM-1 and e-selectin are predictors of diabetes 
(38). Once a protocol is created, different methods of ICAM-1 upregulation can be tested 
in the BVM to ultimately lead to the end goal of testing stents in the BVM.  If ICAM-1 
can be upregulated in the BVM and then stents are tested it would be time and cost 
effective to be able to characterization the stents in vitro before animal models are used.  
 
Challenges 
H&E, immunohistochemistry and immunofluorescence were investigated and 
performed as part of this project.  Background staining was seen through both IHC and 
immunofluorescence; further investigation is required to create a working ICAM-1 
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protocol.  The tonsil tissue seemed very sensitive to the hematoxylin and the time in 
hematoxylin had to be reduced to 2:30 minutes.   
Throughout the attempts of IHC, brown staining was seen in the experimental and 
control samples.  When hydrogen peroxide was used the expression did not seem to be as 
dark.  The changing of the time in the peroxidase substrate did not make much of a 
difference and the change in the concentration of anti-ICAM-1 antibody did not have 
much of an affect either.  The addition of heat treatment to unmask the antigen also did 
not change the background staining seen.   
When the protocol was switched to immunofluorescence, the same problem 
persisted.  Green fluorescing was seen throughout much of the tonsil tissue.  Different 
concentrations were attempted.  Even at a FITC dilution of 1:1000, fluorescing was still 
seen.  To attempt to fix this problem, a different secondary antibody was used and there 
was still background staining.  HUVECs were cultured and used as well, however the 
fixation process must be perfected.  This process could hold potential, however, the 
process of upregulating ICAM-1 is experimental as well.  If there is an error in the 
process of upregulating ICAM-1 then ICAM-1 would not be expressed.  If ICAM-1 is not 
expressed, it would not be known, so therefore it would be unknown if the error were in 
the protocol of upregulating ICAM-1 or detecting if ICAM-1 is upregulated.  The 
HUVECs on ePTFE did show a little bit of fluorescing, however, more so when the 
hydrophobic barrier pen was used, which was later found to be fluorescent itself. 
 
Future Work 
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Future studies could find an alternative to the hydrophobic barrier pen, such 
examples include wax from a candle or a crayon.  These samples could then be compared 
to the tonsil tissue where the hydrophobic barrier pen was used. Another option would be 
to try the HUVECs on ePTFE without the hydrophobic barrier pen, however, this would 
still require that a positive ICAM-1 source be found.  This would be useful to see if the 
background staining is only related to the tonsil tissue.  
A different source of samples that are positive for ICAM-1 must also be found.  It 
is likely due to the fixation of the tonsil tissue that is causing the background staining.  
Since the tonsil tissue cannot be obtained and fixed on the Cal Poly campus, another 
source must be found.  It may be possible to find what tissue in mice would express 
ICAM-1.  This tissue could then be obtained and fixed in histochoice as opposed to 
formalin to prevent the background staining.  
 Cultured cells can also be analyzed further to get a working protocol, if they are 
fixed properly they should remain in the well plates.  If dextran is used however, it is 
uncertain if the protocol of adding dextran, the percent dilution, and incubation time, will 
upregulate ICAM-1.  So if the protocol is used and no ICAM-1 is seen, it will be 
unknown whether it is due to an incorrect protocol or if the HUVECs are not expressing 
ICAM-1.  Santa Cruz Biotechnology uses Hela cells as a positive control for ICAM-1, 
however these cells have been known to be able to take over other cell cultures and could 
be risky to use in the hood with other cells.  
Also, more researchers who have used the same antibody from Santa Cruz 
Biotechnology can be contacted to see if they can provide their working protocol, which 
could be mimicked.   
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All of these are issues that can be assessed further to create a working protocol of 
ICAM-1 leading to the eventual goal of finding stents with the most potential in treating 
diabetic patients. 
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